Diffuse Cutaneous Systemic Sclerosis clinical trials

Explore recruiting diffuse cutaneous systemic sclerosis clinical trials.

Recruiting diffuse cutaneous systemic sclerosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Diffuse Cutaneous Systemic Sclerosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase I/II randomized clinical trial of allogeneic adipose tissue-derived mesenchymal stromal cells systemic infusion in severe systemic sclerosis MSC-AT-SSc

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Netherlands, France

Therapeutic exploratory (Phase II) EU CTIS Study details

T-Guard against Autoreactive T cells in Systemic sclerosis: Erasion and Resolution (TASER)

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis [HZNP-HZN-825-301]

Romania, Austria, Germany, Greece, Spain, Poland +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis

Portugal, Greece, Germany, Spain, Italy, France +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Upfront autologous hematopoietic stem cell transplantation versus immunosuppressive medication in early diffuse cutaneous systemic sclerosis: an international multicentre, open-label, randomized controlled trial (UPSIDE)

Sweden, Netherlands, Italy

Therapeutic use (Phase IV) EU CTIS Study details

Diffuse Cutaneous Systemic Sclerosis trials by city

Diffuse Cutaneous Systemic Sclerosis in Toronto Diffuse Cutaneous Systemic Sclerosis in Vancouver Diffuse Cutaneous Systemic Sclerosis in Montreal Diffuse Cutaneous Systemic Sclerosis in Calgary Diffuse Cutaneous Systemic Sclerosis in Edmonton Diffuse Cutaneous Systemic Sclerosis in Ottawa Diffuse Cutaneous Systemic Sclerosis in Winnipeg Diffuse Cutaneous Systemic Sclerosis in Quebec City Diffuse Cutaneous Systemic Sclerosis in Hamilton Diffuse Cutaneous Systemic Sclerosis in Kitchener Diffuse Cutaneous Systemic Sclerosis in London Diffuse Cutaneous Systemic Sclerosis in Halifax Diffuse Cutaneous Systemic Sclerosis in New York Diffuse Cutaneous Systemic Sclerosis in Los Angeles Diffuse Cutaneous Systemic Sclerosis in Chicago Diffuse Cutaneous Systemic Sclerosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease